1.
|
Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Closed Age: Age not specified Sponsor: Pharmaceutical / Industry Protocol IDs: AVF2941n, NCT00097578
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18527, NCT00121836
|
|
3.
|
Phase: Phase IV Type: Natural history/Epidemiology Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: AVF3991n, NCT00388206
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO19390, NCT00451906
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML21380, NCT00577031
|
|
6.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 04458, P30CA082103, UCSF-04458, NCT00227617
|
|
7.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: AG0501CR, NCT00294359
|
|
8.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D8480C00013, Eudract Number 2005-003440-66, NCT00384176
|
|
9.
|
Phase: Phase III, Phase II Type: Diagnostic, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UKM-MRC-FOCUS3-CR12, FOCUS 3 - CR12, EUDRACT-2008-008323-15, ISRCTN83171665, EU-20960, NCT00975897
|
|
10.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: IFCT-0802, 2009-010187-42, NCT00930891
|
|
11.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068744, E4599, CALGB-E4599, ECOG-4599, NCT00021060
|
|
12.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 3 to 21 Sponsor: NCI Protocol IDs: COG-ACNS0822, ACNS0822, NCT01236560
|
|
13.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENENTECH-AVF2107g, UCLA-0008022, NCT00012233
|
|
14.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GENENTECH-AVF2119g, GUMC-00299, MSKCC-01008, UAB-0028, UAB-F001009003, NCT00012285
|
|
15.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: E-3200, NCT00025337, E3200
|
|
16.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PROLOGUE-SANOFI-ARD5099, SANOFI-ARD5099, NCT00062426
|
|
17.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0303, S0303, ECOG-S0303, NCT00070122
|
|
18.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000335292, U10CA031946, CALGB-90206, CAN-NCIC-REC1, ECOG-CALGB-90206, REC1, NCT00072046
|
|
19.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NO16966, NCT00069095
|
|
20.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000377542, U10CA031946, CALGB-80303, ECOG-80303, NCT00088894
|
|
21.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000427290, U10CA031946, CALGB-90401, ECOG-90401, NCT00110214
|
|
22.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CDR0000427299, P30CA016042, UCLA-0412086-01, ROCHE-BO17920A, NCT00112918
|
|
23.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040249, NCT00115765
|
|
24.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00562, U10CA021115, CDR0000443410, E5202, ECOG-E5202, NCT00217737
|
|
25.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OSI3364g, NCT00130728
|